ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,041 | $5,129 | $2,574 | $3,746 |
| - Cash | $320 | $189 | $115 | $147 |
| + Debt | $52 | $57 | $62 | $56 |
| Enterprise Value | $2,773 | $4,998 | $2,521 | $3,655 |
| Revenue | $958 | $726 | $517 | $484 |
| % Growth | 31.8% | 40.4% | 6.8% | – |
| Gross Profit | $876 | $681 | $507 | $465 |
| % Margin | 91.5% | 93.7% | 98% | 96% |
| EBITDA | $100 | -$68 | -$222 | -$167 |
| % Margin | 10.5% | -9.3% | -42.8% | -34.5% |
| Net Income | $226 | -$61 | -$216 | -$168 |
| % Margin | 23.6% | -8.4% | -41.8% | -34.7% |
| EPS Diluted | 1.36 | -0.37 | -1.34 | -1.05 |
| % Growth | 467.6% | 72.4% | -27.6% | – |
| Operating Cash Flow | $158 | $17 | -$114 | -$126 |
| Capital Expenditures | -$1 | -$40 | $0 | -$1 |
| Free Cash Flow | $157 | -$23 | -$114 | -$127 |